Predictive Oncology Inc (POAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Predictive Oncology Inc (POAI) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($-77.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Predictive Oncology Inc for the company's overall valuation and market capitalisation.
Predictive Oncology Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Predictive Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Predictive Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Predictive Oncology Inc ranked by their cash flow conversion efficiency. Explore Predictive Oncology Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SciDev Limited
F:INFA
|
0.025x |
|
Woojin I&S Co Ltd
KO:010400
|
-0.025x |
|
GUH Holdings Bhd
KLSE:3247
|
-0.035x |
|
IQuest Co. Ltd.
KQ:262840
|
0.001x |
|
Superdong Fast Ferry Kien Giang JSC
VN:SKG
|
N/A |
|
Arima Communications Corp
TW:8101
|
-0.072x |
|
Sensei Biotherapeutics Inc
NASDAQ:SNSE
|
-0.056x |
|
Haily Group Bhd
KLSE:0237
|
0.070x |
Annual Cash Flow Conversion Efficiency for Predictive Oncology Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Predictive Oncology Inc from 2008 to 2024. View Predictive Oncology Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-202.61K | $-11.96 Million | 59.008x | +3800.73% |
| 2023-12-31 | $8.27 Million | $-13.19 Million | -1.595x | -180.55% |
| 2022-12-31 | $21.77 Million | $-12.37 Million | -0.568x | -87.45% |
| 2021-12-31 | $40.27 Million | $-12.21 Million | -0.303x | +93.46% |
| 2020-12-31 | $2.64 Million | $-12.26 Million | -4.638x | -496.57% |
| 2019-12-31 | $11.23 Million | $-8.73 Million | -0.778x | +99.21% |
| 2018-12-31 | $53.47K | $-5.29 Million | -98.890x | -5869.03% |
| 2017-12-31 | $2.69 Million | $-4.46 Million | -1.657x | +65.07% |
| 2016-12-31 | $923.68K | $-4.38 Million | -4.743x | -160.55% |
| 2015-12-31 | $4.11 Million | $-7.49 Million | -1.821x | -397.87% |
| 2014-12-31 | $-5.52 Million | $-3.37 Million | 0.611x | -48.98% |
| 2013-12-31 | $-3.22 Million | $-3.86 Million | 1.198x | +234.13% |
| 2012-12-31 | $-3.30 Million | $-1.18 Million | 0.358x | -45.61% |
| 2011-12-31 | $-2.70 Million | $-1.78 Million | 0.659x | +75.84% |
| 2010-12-31 | $-2.19 Million | $-820.68K | 0.375x | -32.99% |
| 2009-12-31 | $-2.34 Million | $-1.31 Million | 0.559x | -80.78% |
| 2008-12-31 | $-309.44K | $-900.53K | 2.910x | -- |
About Predictive Oncology Inc
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D cult… Read more